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Background: Controlled human malaria infection (CHMI) accelerates development of anti-malarial interventions.
So far, CHMI is done by exposure of volunteers to bites of five mosquitoes carrying Plasmodium falciparum sporozoites
(PfSPZ), a technique available in only a few centres worldwide. Mosquito-mediated CHMI is logistically complex, exact
PfSPZ dosage is impossible and live mosquito-based interventions are not suitable for further clinical development.
Methods: An open-labelled, randomized, dose-finding study in 18–45 year old, healthy, malaria-naïve volunteers was
performed to assess if intravenous (IV) injection of 50 to 3,200 aseptic, purified, cryopreserved PfSPZ is safe and achieves
infection kinetics comparable to published data of mosquito-mediated CHMI. An independent study site verified the
fully infectious dose using direct venous inoculation of PfSPZ. Parasite kinetics were assessed by thick blood smear
microscopy and quantitative real time PCR.
Results: IV inoculation with 50, 200, 800, or 3,200 PfSPZ led to parasitaemia in 1/3, 1/3, 7/9, and 9/9 volunteers,
respectively. The geometric mean pre-patent period (GMPPP) was 11.2 days (range 10.5–12.5) in the 3,200 PfSPZ IV
group. Subsequently, six volunteers received 3,200 PfSPZ by direct venous inoculation at an independent
investigational site. All six developed parasitaemia (GMPPP: 11.4 days, range: 10.4–12.3). Inoculation of PfSPZ
was safe. Infection rate and pre-patent period depended on dose, and injection of 3,200 PfSPZ led to a GMPPP similar
to CHMI with five PfSPZ-infected mosquitoes. The infectious dose of PfSPZ predicted dosage of radiation-attenuated
PfSPZ required for successful vaccination.
Conclusions: IV inoculation of PfSPZ is safe, well tolerated and highly reproducible. It shall further accelerate
development of anti-malarial interventions through standardization and facilitation of CHMI. Beyond this, rational
dose selection for whole PfSPZ-based immunization and complex study designs are now possible.
Trial registration: ClinicalTrials.gov NCT01624961 and NCT01771848.
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Malaria affects almost half of the world’s population and it
is estimated that in 2013 584,000 deaths occurred [1]. The
size of the problem and the ability of Plasmodium spp. to
adapt rapidly to man-made interventions require ex-
pedited development of new anti-malarial tools [2]. To
accelerate clinical development of antimicrobials and vac-
cines, human challenge models are of particular interest.
Controlled human malaria infection (CHMI) with Plas-
modium falciparum is among the best studied challenge
models and has paved the way for many current malaria
vaccine candidates [3] and some drugs for treatment and
chemoprophylaxis [4]. Perhaps the main advantage of
CHMI over studies under natural exposure is that it pro-
vides consistent and predictable infections, which trans-
lates to the ability to conduct simple, well-controlled trials
in a small number of healthy subjects, who do not belong
to a vulnerable group. This results in early, well-founded
decisions on further clinical development.
CHMI by infected mosquitoes requires the bites of five
P. falciparum sporozoite (PfSPZ)-infected mosquitoes to
achieve consistent transmission, whereas one to two
infected mosquitoes produce an infection rate between
50% [5,6] and 83% [7]. This led to the consensus to use
five infected mosquitoes for CHMI, a number that rarely
fails to induce parasitaemia in malaria-naïve volunteers
[5,8] and typically leads to microscopically detectable
parasitaemia nine to twelve days after infection (pre-pa-
tent period). Depending on the laboratory that produces
the PfSPZ-infected mosquitoes numbers required to
achieve consistent infection can be lower [7,9]. Length
of pre-patency varies considerably between centres [10],
which is partly explained by the use of different proce-
dures and parasite isolates. Besides the complexities of
maintaining a suitable insectary, major constraints of
mosquito-mediated CHMI are the restricted time win-
dow during which the mosquitoes can be used for
infection, the logistic challenge of having infected mos-
quitoes and volunteers available at the same time, a large
(and largely unknown) biological variability in the num-
ber of inoculated parasites, and the need for dissection
of mosquitoes after the blood meal to prove infection
and blood intake, which may require re-exposure in
case the mosquitoes are negative. Direct measurement
of the number of mosquito-inoculated PfSPZ in humans is
not possible, and variability in pre-patent period, number of
mosquitoes required for consistent infection [5,7-9] as well
as vaccination success after transmission of attenuated
PfSPZ [11,12] suggests that PfSPZ dose is poorly controlled
by counting the number of bites or mosquitoes. A potential
way to overcome these constraints is injection of purified,
cryopreserved, quantitated PfSPZ. In addition, such inject-
able PfSPZ are being developed and tested as whole-cell
vaccines [13,14].Recently, manufacture of aseptic, vialed, purified, cryo-
preserved, infectious PfSPZ (PfSPZ Challenge) that meet
regulatory standards has been achieved. In four other
clinical trials, PfSPZ Challenge was administered as an
intradermal (ID) or intramuscular (IM) injection and PfSPZ
successfully infected human volunteers at doses between
2,500 and 25,000 PfSPZ [15-18]. However, the pre-
patent period was approximately two days longer than
after mosquito-mediated CHMI, and with ID adminis-
tration there was no dose response.
Here, the results of a CHMI study of PfSPZ Challenge
administered by intravenous (IV) injection through an
indwelling catheter and by direct venous inoculation (DVI)
are reported. The objective of the study was to establish the
minimal number of PfSPZ required to consistently infect vol-
unteers with a pre-patent period comparable to published data
on exposure to the bites of five PfSPZ-infected mosquitoes.
Methods
Study design and participants
The study was an open-labelled PfSPZ Challenge IV
dose-escalation trial with an ID injection control arm
(Tübingen) and a verification group at a second study
site (Barcelona) to assess reproducibility of the best IV
dose. Volunteers were to be healthy and malaria-naïve
individuals between 18 and 45 years of age, who had no
history of malaria or long-term residency in a malaria-
endemic area, never received an investigational malaria
vaccine, were not immunosuppressed, had no acute or
chronic infection or other disease, did not abuse alcohol
or any other drug and belonged to a low-risk group for
cardiac disease [19]. Before enrolment, written informed
consent was obtained and understanding of the study
and procedures was assessed with a quiz. The study re-
ceived approval by the ethics committee of the Univer-
sity Clinic and the Medical Faculty of the University of
Tübingen, and in Barcelona by the ethics committees of
the Hospital Clinic and the Hospital de la Santa Creu i
Sant Pau. The study followed the principles of the Dec-
laration of Helsinki in its 6th revision as well as Inter-
national Conference on Harmonization – Good Clinical
Practice (ICH-GCP) guidelines. The study is registered
with ClinicalTrials.gov, numbers NCT01624961 and
NCT01771848.
In Tübingen, volunteers were randomly assigned to the
IV or ID arm by a computer-generated sequence provided
in sealed envelopes by a third party on the day of PfSPZ
Challenge injection (Day 0). The injections took place be-
tween June 12 and September 12, 2012. Safety follow-up
of volunteers was done for six months. Dose-escalation of
PfSPZ Challenge IV was in four-fold increases, starting
with 50 and ending with a maximal dose of 3,200 PfSPZ.
At each dose, three volunteers were injected and if 3/3 be-
came parasitaemic within three weeks another six were
Table 1 In vitro infectivity to a hepatocyte line (HC-04)
(potency) and sporozoite membrane integrity (viability)
of the two lots of PfSPZ Challenge
A) Tübingen
Release date Potency ± standard deviation
(No. of parasites expressing
PfMSP-1/well)
Viability ± standard
deviation
Fresh* 32.7 ± 1.5 parasites 98.2%
Release** 29.3 ± 3.1 parasites 87.4% ± 5.9%
3 months 27.3 ± 0.6 parasites 84.6% ± 1.9%
6 months 26.7 ± 1.5 parasites 83.6% ± 5.5%
9 months 26.3 ± 2.5 parasites 86.3% ± 6.5%
12 months 27.3 ± 0.6 parasites 86.2% ± 1.3%
Post last clinical
dose Tübingen
24.0 ± 1.7 parasites 81.7% ± 2.6%
B) Barcelona
Release date Potency ± standard deviation
(No. of parasites expressing
PfMSP-1/well)
Viability ± standard
deviation
Fresh* 28.3 ± 1.5 parasites 95.5%
Release** 25.3 ± 1.5 parasites 89% ± 2.2%
3 months 21.7 ± 1.5 parasites 85% ± 3.3%
6 months 25.0 ± 5.3 parasites 86% ± 4.8%
Post last clinical
dose Barcelona
19.0 ± 1.0 parasites 85% ± 4.4%
*Fresh refers to the aseptic, purified PfSPZ of this lot before they were
cryopreserved. Data from all other time points were generated on thawed
PfSPZ Challenge.
**Release refers to the data generated within a few weeks of manufacture that
were used to demonstrate that PfSPZ Challenge met quality control “release”
specifications. All other data are from the formal stability programme.
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the next level when less than 3/3 or less than 9/9 became
parasitaemic. A further dose increase was planned if 9/9
volunteers became parasitaemic but the geometric mean
pre-patent period was greater than 12 days. ID injections
were given as two separate doses of 50 μL containing 1,250
PfSPZ in the deltoid region of each arm. In Tübingen,
PfSPZ Challenge IV was administered as a slow injec-
tion of 0.5 mL via an IV catheter preceded and followed
by a flush with at least 2 mL of physiological saline. In
Barcelona, an IV catheter was inserted in the left arm to
serve as emergency access. PfSPZ were administered by
direct venous inoculation (DVI) of 0.5 mL parasite sus-
pension into the right arm by venipuncture using a 1 mL
syringe with 25 G × 16 mm needle on April 19, 2013.
PfSPZ Challenge
PfSPZ Challenge contains aseptic, purified, cryopre-
served NF54 PfSPZ, isolated from Anopheles stephensi
mosquitoes, reared and infected under aseptic conditions
[14,20]. NF54 is susceptible to all clinically used anti-
malarials and has been used extensively in CHMI experi-
ments [8]. PfSPZ Challenge was kept at -195 to -150°C in
liquid nitrogen vapour phase. Two separate lots of PfSPZ
Challenge, produced 16 months apart (March 2011 and
July 2012), were used in the study. PfSPZ Challenge re-
leased for clinical use meets quality control specifications
including sterility, purity and potency [14,20]. The quality
control release and stability programme assessed potency
and viability using in vitro infection of cultured human
hepatocytes (HC-04) and a membrane integrity assay
(Table 1), respectively as described [14,20]. Briefly, 50,000
PfSPZ were added to 40,000 HC-04 (1F9) cells and cul-
tured for six days. Late liver stage parasites were detected
by staining with a monoclonal antibody against P. falcip-
arum merozoite protein 1. Membrane integrity was tested
by fluorescence microscopy of PfSPZ following incubation
with SYBR green and propidium iodide. Volunteers were
inoculated within 30 minutes after thawing of PfSPZ
Challenge.
Procedures
All volunteers were observed for at least one hour after
PfSPZ Challenge administration (Day 0) and examined
on the subsequent day (Day 1) followed by daily tele-
phone or electronic mail contacts. In Tübingen, twice-
daily visits and thick blood smears were performed from
Day 5 until the first thick blood smear was positive or
Day 21 was reached. In Barcelona, once-daily visits were
performed between Days 6 and 9, followed by twice-
daily visits between Days 10 and 15. Quantitative thick
blood films were prepared as described [21] at least once
a day. Two or more microscopists were required to ob-
serve a minimum of two unambiguous parasites to declarea slide positive with a limit of detection below four para-
sites per μL. On the day of first microscopically detectable
parasitaemia or Day 21 (if no parasites had been detected
by then) volunteers started a curative anti-malarial treat-
ment with artemether-lumefantrine (Tübingen) or chloro-
quine (Barcelona). Subjects were considered cured when
two consecutive thick blood smears were negative and
symptoms ceased. Later follow-up visits of volunteers oc-
curred on Days 28, 84 and 168 after inoculation in Tübin-
gen, and on Days 35 and 90 in Barcelona. Adverse events
(AE) and clinical symptoms were reviewed daily until Day
21 and on all follow-up visits thereafter.
DNA from blood was isolated before PfSPZ Challenge
administration and every second day beginning on Day 5
in Tübingen or every time a blood smear was taken to
perform a thick blood smear in Barcelona. Parasitaemia
was estimated by quantitative polymerase chain reaction
(qPCR) as described previously [22]. DNA extraction of
blood samples and a dilution from ring stage parasite
culture was done in the presence of an extraction control
(DEC 610, Bioline) using silica spin columns (Qiagen).
Amplification and detection of fluorescence was done
with a RotorGene 3000 (Corbett). Limit of quantification
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blood smear, qPCR procedures were not fully validated
and were considered exploratory. All qPCR runs were per-
formed after completion of the trial.
Objectives
The primary objective of the study was to identify a
PfSPZ Challenge dose that safely infects 9/9 volunteers
after intravenous injection and the secondary objective
was to assess if increasing the PfSPZ Challenge dose
results in a pre-patent period of twelve or less days. Suc-
cessful infection was defined as the appearance of asex-
ual parasites in peripheral blood, detected by thick blood
film microscopy. Upon completion of the trial in Tübingen
it was clear that the objectives regarding infection rate and
pre-patent period had been achieved. It was, therefore, de-
cided to verify reproducibility of the successful dose of
3,200 PfSPZ IV in an independent group (n = 6) at a differ-
ent study site in Barcelona, and to use DVI instead of injec-
tion through an in-dwelling catheter to administer PfSPZ
Challenge.
Statistical analysis
A one parameter exponential model was used to model
the effect of dose on the probability of infection [23]. The
effect of dose on length of pre-patent period was modelled
under the assumptions that volunteers who did not de-
velop parasitaemia until Day 21 had no risk of developing
parasitaemia thereafter and that the relationship between
dose and pre-patent period was linear. Parasitaemia on
the day of first positive thick blood smear was used as a
covariate in the model. Dose and parasitaemia were log10-
transformed. PCR data were used to estimate parasite
multiplication rates using a mixed linear model with vol-
unteer as random variable and PfSPZ Challenge dose and
time as independent variables. Safety and tolerability data
were analysed by descriptive and visual methods following
published guidelines and grading schemes for clinical and
laboratory abnormalities [24]. Calculations were done with
R version 2.15.2 [25] and a two-sided p < 0.05 was consid-
ered statistically significant.
Results
Dose escalation of intravenous PfSPZ Challenge
A total of 30 volunteers with similar demographic char-
acteristics were included in the dose-escalation phase of
the trial (Table 2). Six received 2,500 PfSPZ Challenge
ID and 24 IV (Figure 1). PfSPZ Challenge ID led to four
successful infections with a geometric mean pre-patent
period of 13.6 days (Table 3). The infection rate and pre-
patent period of PfSPZ Challenge ID were comparable
to what was achieved with 2,500 PfSPZ ID in previous
studies [16,15]. The PfSPZ Challenge IV dose was in-
creased sequentially from 50 (n = 3), to 200 (n = 3), to800 (n = 9) and finally to 3,200 (n = 9) PfSPZ. Injection
of 50, 200 and 800 PfSPZ IV led to asexual erythrocytic
stage parasitaemia in 1/3, 1/3 and 7/9 volunteers, re-
spectively. In contrast, injection of 3,200 PfSPZ led to
asexual erythrocytic stage parasitaemia in 9/9 (100%)
volunteers (Table 3). Statistical modelling of probability
of infection (Figure 2) with an exponential model [23]
estimates an 50% infectious dose of 326 PfSPZ (95%
confidence interval [CI]: 169–662).
A geometric mean pre-patent period not longer than
twelve days was observed in the 800 PfSPZ (11.7 days)
and 3,200 PfSPZ (11.2 days) groups (Figure 3). In the IV
groups, dose, corrected for parasite density, explained
73% of variability in pre-patent period and every tenfold
increase in dose of PfSPZ led to a 36 (95% CI: 23–48)
hours reduction in pre-patent period. This is in contrast
to published data [26] on the dose-response relationship
between number of mosquitoes and pre-patent period
(Figure 4).
Dose verification
Six volunteers received 3,200 PfSPZ Challenge by DVI by
an independent team in Barcelona. All (6/6) became para-
sitaemic with a geometric mean of 11.4 days (Table 3). All
volunteers at both sites were treated with an anti-malarial,
either when thick blood smears became positive or on
Day 21 in those who still had a negative thick blood
smear.
Early parasite kinetics measured by qPCR
All blood smear results were confirmed by qPCR and
none of the microscopically negative volunteers reached
the positivity threshold. On average, qPCR detected para-
sites 65 (range 2–167) hours before microscopy. The pat-
tern of parasite multiplication did not show pronounced
synchronicity (Figure 5). The estimated parasite multipli-
cation rate per 48 hours until the first positive thick blood
smear, was 10.2 (95% CI 5.0–21.0).
Safety and tolerability of PfSPZ Challenge
Overall, IV injection of PfSPZ Challenge through a cath-
eter and by DVI was very well tolerated. Nevertheless, one
volunteer (800 PfSPZ group) experienced mild nausea ten
hours after injection, which was considered possibly re-
lated to PfSPZ Challenge administration. No other indi-
vidual experienced a PfSPZ injection-related AE. A total
of 28 volunteers developed parasitaemia detected by thick
blood smear and all developed at least one symptom char-
acteristic of malaria. A total of 286 adverse events (AE) oc-
curred in 34 of the 36 volunteers. The vast majority of
AEs happened around the time when parasitaemia be-
came detectable by microscopy (Figure 6). Most AEs were
mild (Grade 1; n = 232). Fourteen volunteers experienced
Table 2 Demographic characteristics of the participants
Variable Total ID 2500 IV 50 IV 200 IV 800 IV 3200 DVI 3200
N 36 6 3 3 9 9 6
Age in years* 26 (19; 43) 24 (21; 42) 24 (23; 27) 27 (27; 32) 26 (21; 43) 27 (24; 30) 29 (19; 40)
Gender, Female:Male# 11:25 1:5 0:3 0:3 4:5 2:7 4:2
Height in cm* 176 (159; 196) 178 (166; 196) 186 (178; 190) 169 (167; 186) 177 (166; 189) 176 (163; 196) 167 (159; 172)
Weight in kg* 73 (55; 111) 83 (63; 92) 77 (70; 100) 77 (68; 82) 74 (59; 90) 71 (64; 111) 61.1 (55; 73)
BMI in kg/m2* 23.9 (18.5; 29.4) 24.1 (22.9; 29.4) 22.1 (21.3; 28.9) 24.3 (22.3; 28.7) 23.8 (19.1; 26.6) 24.1 (18.5; 28.8) 22.8 (19.1; 24.8)
Hb in g/dl* 14.7 (11.8; 16.7) 15.1 (12.5; 15.3) 15.6 (15.1; 16.2) 16.1 (14.7; 16.7) 14.2 (12.0; 16.6) 14.6 (11.8; 15.7) 13.3 (12.3; 15.1)
Platelets/nL* 248 (138; 396) 231 (172; 260) 237 (138; 340) 263 (210; 307) 221 (176; 261) 246 (193; 396) 321 (259; 364)
*Median (min; max), #N, ID: intradermal, IV: intravenous (dose-escalation group), DVI: direct venous inoculation (verification group).
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ively (Table 4). No serious AE (SAE) occurred.
The most frequent AE was headache (n = 58, 6 Grade
2). This was followed by fatigue (n = 35, 5 Grade 2) and
fever or fever-associated symptoms (n = 32, 9 Grade 2, 2
Grade 3). Laboratory abnormalities included liver en-
zyme increases (n = 7), lymphopenia (n = 8) and bilirubi-
nuria (n = 2). All resolved uneventfully and there were
no delayed onset AEs.
Discussion
Two previous studies have shown that PfSPZ Challenge
can infect malaria-naïve volunteers following ID [16]
and IM [15] injection but parasite kinetics, number of
PfSPZ required and infection rate are different from
mosquito-mediated CHMI. The present study found that
3,200 aseptic, purified, cryopreserved PfSPZ adminis-
tered by IV injection consistently infected all subjects
(15/15) with P. falciparum malaria and resulted in a pre-Figure 1 Trial profile. In Tübingen the IV dose of PfSPZ Challenge IV was
to 3,200 PfSPZ (4). In steps 1 and 2, volunteers were randomly assigned to
(3,200 PfSPZ DVI) in Barcelona was added after completion of the 3,200 PfSpatent period of 10.4–12.5 days, which is comparable to
the pre-patent period often observed in volunteers ex-
posed to the bites of five PfSPZ (NF54)-infected mosqui-
toes [13,14,27]. It also demonstrated that the infectivity
increased from 33% to 100% and the geometric mean
pre-patent period was reduced from >13 days to 11.2 days
as the dose of PfSPZ was increased from 50 to 3,200. Im-
portantly, IV administration of PfSPZ Challenge was safe
and well tolerated and the results were reproduced at an-
other site that used a different lot of PfSPZ, a different
clinical team, and a simplified method of injection (DVI).
Kinetics of mosquito- and IV PfSPZ Challenge-mediated
CHMI are very comparable. Mosquitoes deposit PfSPZ in
blood vessels and into the skin, where some of them get ac-
cess to the vascular system [28]. Since it has been sug-
gested that the “skin stage” of malaria has an important
role in immunity [29], it would be interesting to compare
immune responses to IV and mosquito-mediated P. falcip-
arum malaria in direct comparison. However, it should beincreased sequentially in 4 steps from 50 (1), to 200 (2), to 800 (3) and
receive PfSPZ Challenge ID or IV. An independent verification group
PZ IV group in Tübingen.
Table 3 Infection rate, pre-patent period and time to malaria
Group Inoculated (N) Parasitaemic (N) Prepatent period in days* (Days) Incubation period‡ (Days)
ID 2500 6 4 13.6 (12.3 – 15.3) 14.2 (13.0 – 16.0)
IV 50 3 1 13.3 (NA) 7.5 (NA)
IV 200 3 1 13.9 (NA) 15.0 (NA)
IV 800 9 7 11.7 (10.9 – 12.5) 12.0 (11.0 – 13.5)
IV 3200 9 9 11.2 (10.5 – 12.5) 9.5 (7.0 – 12.5)
DVI 3200 6 6 11.4 (10.4 – 12.3) 10.6 (10.0 – 12.0)
*Time from inoculation to first positive thick blood smear, given as geometric mean (min–max).
‡Time from inoculation to first symptom judged at least possibly related to malaria, given as geometric mean (min–max).
NA: not applicable, ID: intradermal, IV: intravenous, DVI: direct venous inoculation (verification group).
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tion of mice against malaria by immunization with radi-
ation attenuated sporozoites in 1967 [30], almost all work
in animal models to develop and understand radiation
attenuated sporozoite-induced immunity has used IV
immunization and IV challenge. Furthermore, it has re-
cently been shown that mosquitoes directly cannulate
small vessels when feeding [31].
Notwithstanding the “non-natural” mode of adminis-
tration, several important advantages emanate from the
successful translation of mosquito-mediated to mos-
quito-free inoculation of PfSPZ for CHMI: I) improved
standardization, II) exact dosing and dose-estimation0.00
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hardly possible using mosquito-mediated CHMI [10].
Conversion of number of mosquitoes into PfSPZ dose
cannot be exact. Nevertheless, data of this study helps
to improve dose-estimation for immunization trials.
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mosquito. The task of rational dosing becomes even more
complicated when the biologically more relevant variable
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ther research and technological progress, since the in-
fected hepatocyte is a crucial immunogen in PfSPZ-based
immunization strategies and hence shall be directly moni-
tored to ensure high-level protection. Results of the firstID
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ver time from Day 0 through Day 21. Shades of blue represent AE
nteer IDs with a star indicate those volunteers who did not develop
letter ‘M’ in red.
Table 4 Grade 2 and Grade 3 adverse events
Group Grade 2* Grade 3*
ID 2500 (n = 6) Fatigue (2) None
Fever (1)
Headache (2)
Tachycardia (2)
High ALT (1)
IV 50 (n = 3) Fever (1) None
IV 200 (n = 3) Fever (1) None
Headache (1)
Tachycardia (1)
IV 800 (n = 9) None Lymphopenia (1)
IV 3200 (n = 9) Fatigue (2) None
Fever (2)
DVI 3200 (n = 6) Anxiety (2) High CRP (1)
Contusion (1)
Common cold (1)
Fatigue (1)
Fever (4) Fever (2)
Headache (3)
High ALT (2)
High AST (1)
High CRP (1)
Insomnia (1)
Low potassium (1) Lymphopenia (3)
Malaise (1)
Menstrual cramps (1)
Myalgia (4)
Nausea (2)
Neutropenia (1)
Stye (1)
Vomiting (2)
Weakness (1)
Total N 47 7
Note that volunteers in the verification group underwent a more extensive
blood-sampling scheme for laboratory parameters. Laboratory parameters
were graded using an adapted U.S. FDA toxicity scale.
*Symptom (N), ID: intradermal, IV: intravenous, DVI: direct venous inoculation
(verification group).
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PfSPZ Challenge for the chemoprophylaxis with sporozo-
ites approach [33,34], are expected in early 2015 [35].
So far, CHMI with mosquitoes is restricted to a small
number of centres globally. Development of a standard-
ized protocol for CHMI with PfSPZ Challenge enables
every malaria-experienced centre to perform CHMI
studies to assess anti-malarial drugs and vaccines, diag-
nostics, and innate and acquired resistance to malaria. Due
to the high reproducibility and temporal independence,previously unfeasible study designs can be realized; from
complex early phase (e.g. sequential and adaptive) to large
multicentre trials in populations with very low natural ex-
posure (e.g. travellers and populations in pre-eradication
settings) and studies in endemic countries. In fact, the first
CHMI trial using PfSPZ Challenge IV is underway in
Gabon and several parallel trials are in progress to assess
PfSPZ Vaccine IV in the United States, Europe and Africa.
Conclusions
Exposure to five infected mosquitoes is a standard tech-
nique for controlled human malaria infection (CHMI) in
humans. Successful translation of mosquito-administered
to injectable Plasmodium falciparum sporozoite (PfSPZ)
mediated CHMI is an important step in standardization
and harmonization of CHMI. It allows complex and larger
multicentre trials and increases the number of groups with
access to CHMI in times of active development of novel
preventive and therapeutic interventions. CHMI using
intravenous inoculation of PfSPZ Challenge is safe, well
tolerated, highly reproducible and shall boost the under-
standing of malaria and the development of novel anti-
malarial interventions.
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